Related references
Note: Only part of the references are listed.An enhanced prognostic score for overall survival of patients with cancer derived from a large real-world cohort
T. Becker et al.
ANNALS OF ONCOLOGY (2020)
The association of PD-L1 expression with the efficacy of antiPD-1/PD-L1 immunotherapy and survival of non-small cell lung cancer patients: a meta-analysis of randomized controlled trials
Yangyang Xu et al.
TRANSLATIONAL LUNG CANCER RESEARCH (2019)
Predictive biomarkers of response for immune checkpoint inhibitors in non-small-cell lung cancer
Arsela Prelaj et al.
EUROPEAN JOURNAL OF CANCER (2019)
Characteristics and Predictive Value of PD-L1 Status in Real-World Non-Small Cell Lung Cancer Patients
Jeng-Sen Tseng et al.
JOURNAL OF IMMUNOTHERAPY (2018)
Angiotensin converting enzyme inhibitors and risk of lung cancer: population based cohort study
Blanaid M. Hicks et al.
BMJ-BRITISH MEDICAL JOURNAL (2018)
Lung cancer: current therapies and new targeted treatments
Fred R. Hirsch et al.
LANCET (2017)
Serum calcium, alkaline phosphotase and hemoglobin as risk factors for bone metastases in bladder cancer
Ping Huang et al.
PLOS ONE (2017)
Predictive Factors for Poor Progression-free Survival in Patients with Non-small Cell Lung Cancer Treated with Nivolumab
Yoshihiko Taniguchi et al.
ANTICANCER RESEARCH (2017)
Pretreatment Serum Albumin Level is an Independent Prognostic Factor in Patients with Stage IIIB Non-Small Cell Lung Cancer: A Study of the Turkish Descriptive Oncological Researches Group
Ozgur Tanriverdi et al.
Asian Pacific Journal of Cancer Prevention (2015)
Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer
Edward B. Garon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer
Julie Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer
H. Borghaei et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Modeling the overall survival of patients with advanced-stage non-small cell lung cancer using data of routine laboratory tests
Kejin Zhang et al.
INTERNATIONAL JOURNAL OF CANCER (2015)
Regularization Paths for Cox's Proportional Hazards Model via Coordinate Descent
Noah Simon et al.
Journal of Statistical Software (2015)
Predictors of survival for younger patients less than 50 years of age with non-small cell lung cancer (NSCLC): A California Cancer Registry analysis
Matthew S. Lara et al.
LUNG CANCER (2014)
A Laboratory Prognostic Index Model for Patients with Advanced Non-Small Cell Lung Cancer
Arife Ulas et al.
PLOS ONE (2014)
Prognostic and predictive factors for lung cancer
Marianne Paesmans
BREATHE (2012)
Use of angiotensin-converting-enzyme inhibitors or angiotensin-receptor blockers and cancer risk: a meta-analysis of observational studies
Chan Yoon et al.
CANADIAN MEDICAL ASSOCIATION JOURNAL (2011)
Multiple imputation using chained equations: Issues and guidance for practice
Ian R. White et al.
STATISTICS IN MEDICINE (2011)
The impact of additional prognostic factors on survival and their relationship with the anatomical extent of disease expressed by the 6th edition of the TNM classification of malignant tumors and the proposals for the 7th edition
Jean-Paul Sculier et al.
JOURNAL OF THORACIC ONCOLOGY (2008)
Share Paper
